Drug intelligence / Profile preview

Lianling Zhiyang Granule

Development stage: Unknown
Lead developer: Third Affiliated Hospital, Beijing University of Chinese Medicine
Administration: Oral

Overview

Lianling Zhiyang Granule is a traditional Chinese medicine (TCM) formulation developed by the Third Hospital affiliated to Beijing University of Chinese Medicine. It is specifically designed for the treatment of atopic dermatitis, particularly in patients diagnosed with the "heart fire and spleen deficiency" syndrome according to TCM principles. The formulation aims to alleviate pruritus (itching) and reduce skin inflammation. As a granule-based therapy, it is administered orally. The drug is currently undergoing clinical evaluation to assess its therapeutic efficacy and safety, as well as to support its formulation development.

Brand names: lianling zhiyang granule
Other names: Lian Ling Itch Relieving Granules

Beyond the preview

Go deeper on Lianling Zhiyang Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lianling Zhiyang Granule.

Explore the full profile